Mr Brian T Pavlue, PAC | |
1225 E Mineral Rd, Gilbert, AZ 85234-4461 | |
(917) 301-4953 | |
Not Available |
Full Name | Mr Brian T Pavlue |
---|---|
Gender | Male |
Speciality | Physician Assistant |
Location | 1225 E Mineral Rd, Gilbert, Arizona |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1730371998 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 1972023 (Wisconsin) | Secondary |
363A00000X | Physician Assistant | 4384 (Arizona) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Brian T Pavlue, PAC 1225 E Mineral Rd, Gilbert, AZ 85234-4461 Ph: (917) 301-4953 | Mr Brian T Pavlue, PAC 1225 E Mineral Rd, Gilbert, AZ 85234-4461 Ph: (917) 301-4953 |
News Archive
The East Midlands Academic Health Science Network, NHS Leadership Academy and the East Midlands Leadership Academy, have signed a unique national partnership agreement, embedding clear commitment and leadership in the NHS.
Houston, Texas, the home base of Rainbow Coral Corp.'s biosciences division, is bursting with potential customers for n3D's Bio-Assembler system. Just last month, the largest stem cell lab and bank in North America opened in Sugar Land, the city's fastest-growing suburb.
Breast cancers that arise sporadically, rather than through inheritance of certain genes, likely start with defects of DNA repair mechanisms that allow environmentally triggered mutations to accumulate, according to researchers at the University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC and the University of Pittsburgh Cancer Institute.
Angiotech Pharmaceuticals, Inc. today announced that the affected creditors of Angiotech and certain of its subsidiaries (collectively, the "Angiotech Entities") have unanimously approved the Second Amended and Restated Plan of Compromise or Arrangement concerning, affecting and involving the Angiotech Entities pursuant to the Companies' Creditors Arrangement Act (Canada).
The mere mention of gene editing and DNA altering might conjure up images of designer babies, but that is not what researcher Jin Liu has in mind.
› Verified 7 days ago